Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Asthma and Allergy"
DOI: 10.2147/jaa.s258594
Abstract: Abstract Severe refractory asthma (SRA) still has a high economic and social impact, including a reduction in quality of life (QoL), productivity, a greater risk of exacerbations and emergency department (ED) visits. Another major issue… read more here.
Keywords: eosinophilic asthma; biological drugs; review; therapies severe ... See more keywords
Switching Biological Therapies in Severe Asthma
Sign Up to like & getrecommendations! Published in 2023 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms24119563
Abstract: Currently, three classes of monoclonal antibodies targeting type 2 inflammation pathways are available in Italy for the treatment of severe asthma: anti-IgE (Omalizumab), anti-IL-5/anti-IL-5Rα (Mepolizumab and Benralizumab), and anti-IL-4Rα (Dupilumab). Numerous randomized controlled trials (RCTs)… read more here.
Keywords: biological therapies; therapies severe; anti; treatment ... See more keywords